YDYi-Wu Dang

Yi-Wu Dang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Wu Dang has a total of 228 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Chen

    Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

    36 shared publications
  • Rong-Quan He

    Department of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China

    9 shared publications
  • Dan-Dan Xiong

    Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, P.R. China

    8 shared publications
  • Gang Chen

    Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    8 shared publications
  • Jian-Di Li

    Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    6 shared publications
  • Li-Min Liu

    Department of Toxicology, College of Pharmacy, Guangxi Medical University, Nanning, P.R. China

    6 shared publications

Latest Publications

  • Open Access

    Epigenetic activation of SLC7A11 defines a ferroptosis—immune axis and enables robust DNA methylation-based diagnosis of lung squamous cell carcinoma

    by Hui-Ping Lu, Kesong Nong, Lingling Pang, Yulu Tang, Qi Li, Zhendong Chen, Li Xiao, Liangqin Zhu, Dongming Li, Yiyang Chen, et al.

    Background: Lung squamous cell carcinoma (LUSC) currently lacks reliable biomarkers for early diagnosis and precision therapy. While Solute Carrier Family 7 Member 11 (SLC7A11) plays key roles in ferroptosis resistance, redox homeostasis and tumor progression, its epigenetic regulation, diagnostic potential, and immunological functions in LUSC remain poorly understood. Methods: Multi-omics data from The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Gene Expression Omnibus (GEO) and an in-house cohorts of 173 LUSC patients were integrated to characterize SLC7A11 DNA methylation, mRNA, and protein levels. Four methylation probes were utilized to construct diagnostic models, including Generalized Linear Model (GLM), Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Extreme Gradient Boosting (XGB). These models were validated internally ( via 10-fold cross-validation and bootsrtapping) and externally using the GSE121849 dataset. Model interpretability was examined through SHapley Additive exPlanations (SHAP). Additionally, immune infiltration, pathway enrichment and drug sensitivity analyses were performed to explore ferroptosis-associated and immunity-related mechanisms. Results: SLC7A11 exhibited LUSC-specific epigenetic activation, characterized by promoter hypomethylation, mRNA upregulation, and protein overexpression across cohorts. The four-probe GLM diagnostic model achieved superior performance (AUC = 0.985 in TCGA; AUC = 1.000 in GSE121849), with SHAP identifying cg02102889 (TSS1500) as the most influential probe. While SLC7A11 expression and methylation were not significantly associated with survival in the overall cohort, high SLC7A11 predicted poorer outcomes in female patients and those with pathologic T3 & T4 stage disease. Mechanistically, SLC7A11-high tumors displayed ferroptosis-resistant and immunosuppressive phenotypes, including increased Programmed Death-Ligand 1 (PD-L1) expression and enrichment of regulatory T cells and M2 macrophages. Drug sensitivity profiling suggested resistance to Reactive Oxygen Species (ROS) inducers and Histone Deacetylase (HDAC) inhibitors, but enhanced sensitivity to recombinant tumor necrosis factor-related apoptosis-inducing ligand (rTRAIL) and 17-Allylamino-17-demethoxygeldanamycin. Conclusion: SLC7A11 undergoes epigenetic activation in LUSC and enables a robust four-probe, methylation-based diagnostic model. Its expression is linked to ferroptosis resistance, immune evasion, and therapeutic response, supporting SLC7A11 as a promising biomarker for early diagnosis and personalized treatment in LUSC.


  • Open Access

    Molecular mechanism and biological pathway of high-expressed RAD51 in regulating cell adhesion and potentially affecting oral squamous cell carcinoma

    by Yu-Xing Tang, Yu-Yan Pang, Yan Cui, Guo-Jiao Wu, Lin-Qing Huang, Chang-Zhan Zhou, Bin Li, Qi Li, Bang-Teng Chi, Rong-Quan He, et al.

    Background Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral cavity, with over 70% of cases detected in advanced stages and a 5-year survival rate of 50%. RAD51, a crucial DNA repair molecule, has also been implicated in the regulation of cell adhesion. However, its multi-platform expression patterns and functional role in cell adhesion within the context of OSCC have not yet been comprehensively validated. Methods Bulk RNA (RNA-seq and microarray), immunohistochemistry (IHC), and single-cell sequencing (scRNA-seq) were used to assess RAD51 expression and its clinical relevance in OSCC. CRISPR was used to knock out RAD51 and explore its effect on OSCC cell proliferation. Bulk RNA and scRNA-seq analyses were integrated to explore RAD51’s molecular mechanisms, cellular communication, and metabolic pathways. Drug sensitivity analysis aimed to explore the relationship between RAD51 and drugs, while the target molecules of RAD51 transcription factors were identified. Results In bulk RNA (1,006 OSCC samples), IHC (162 OSCC tissues), and scRNA-seq (9,693 malignant epithelial cells), RAD51 was comprehensively upregulated in OSCC. The proliferation of OSCC cells was inhibited due to knockout of RAD51. Bulk RNA and scRNA-seq indicated that RAD51 was associated with cell adhesion. High expression of RAD51 was associated with the MIF pathway in cell communication, with the TCA cycle metabolism being mainly regulated. The expression of RAD51 was associated with resistance to Erlotinib, Gefitinib, and Selumetinib. In the molecular network, RAD51 was demonstrated a targeting relationship with adhesion-related molecules like CD74, JUP and MIF. Conclusion High expression of RAD51 may promote the advancement of OSCC by regulating the related mechanisms of cell adhesion.


  • Open Access

    Nitidine chloride inhibits the progression of hepatocellular carcinoma by suppressing IGF2BP3 and modulates metabolic pathways in an m6A-dependent manner

    by Dan-Dan Xiong, Zhen-Dong Chen, Jian-Di Li, Yu-Long Deng, Rong-Quan He, Zhi-Guang Huang, San-Qi An, Yi-Wu Dang, Gang Chen

    Background: Hepatocellular carcinoma (HCC) stands as a major health concern due to its significant morbidity and mortality. Among potential botanical therapeutics, nitidine chloride (NC) has garnered attention for its potential anti-HCC properties. However, the underlying mechanisms, especially the possible involvement of the m6A pathway, remain to be elucidated. Methods: HCC cell and zebrafish xenograft models were utilized to validate the anti-HCC effects of NC. RNA-seq and MeRIP-seq analyses were performed to explore the potential targets and mechanisms of NC against HCC. The target effect of NC on IGF2BP3 was verified through RT-qPCR, WB, molecular docking, molecular dynamics (MD) simulation, surface plasmon resonance (SPR), and CCK8 off-target assays. Downstream target genes were confirmed using RNA stability assays. Results: In this study, utilizing HCC cell and zebrafish xenograft models, we validated NC’s ability to inhibit the growth, metastasis, and angiogenesis of HCC. Subsequently, employing RNA sequencing, RT-qPCR, WB, molecular docking, MD simulation, SPR, and CCK8 off-target assays, we pinpointed IGF2BP3 as a direct target of NC. IGF2BP3 is highly expressed in HCC, and IGF2BP3 knockdown significantly inhibited the proliferation, migration and invasion of HCC cells. Further MeRIP-seq and RIP-seq revealed 197 genes interacting with IGF2BP3, downregulated at mRNA and m6A levels after NC treatment, primarily associated with multiple metabolism-related pathways. Through intersection analysis, we pinpointed 30 potential metabolic target genes regulated by NC through IGF2BP3. Based on the expression of these genes, the metabolic scores for each HCC patient were calculated. Our findings suggest that patients with high metabolic scores have poorer prognoses, and the metabolic score serves as an independent prognostic factor. Finally, RNA stability experiments confirmed CKB, RRM2, NME1, PKM, and UXS1 as specific metabolic target genes affected by NC/IGF2BP3, displaying reduced RNA half-life post IGF2BP3 downregulation. Conclusion: Our study suggest that NC may exert its anti-HCC effects by downregulating IGF2BP3, inhibiting the m6A modification levels of metabolic-related genes, thereby reducing their stability and expression. Such insights provide a new direction in the study of NC’s anti-HCC mechanisms and offer novel perspectives for the treatment of HCC patients, focusing on both metabolic levels and m6A modification levels.


  • A Comprehensive Analysis of LYAR in Colorectal Cancer: Prognostic Marker and Therapeutic Target

    by Jia-Ying Wen, Ye-Ying Fang, Dong-Ming Li, Yu-Lu Tang, He-Qing Huang, Li-Min Liu, Jiang-Hui Zeng, Yi-Wu Dang, Yan-Fang Pan, Da-Tong Zeng, et al.

    Background: Colorectal cancer (CRC) is a major global health challenge with a need for new biomarkers and therapeutic targets. This work investigated the biological mechanisms and clinical value of Ly1 antibody reactive (LYAR) in CRC. Methods: We analyzed LYAR mRNA expression across multiple public databases, including genotype-tissue expression, gene expression omnibus, Oncomine, and the cancer genome atlas, alongside in-house immunohistochemical data to evaluate LYAR protein expression in CRC and non-CRC colorectal tissues. Gene set enrichment analysis (GSEA) was used to elucidate LYAR’s biological functions, and its impact on the tumor immune microenvironment was assessed using CIBERSORT, ESTIMATE, and single-cell RNA sequencing techniques. In addition, LYAR’s association with clinicopathological features and patient prognosis was explored, and its influence on drug sensitivity was investigated using the Connectivity Map database. Results: LYAR was significantly upregulated in CRC tissues compared with non-CRC colorectal counterparts, associated with altered immune cell composition and enhanced RNA processing, splicing, and cell cycle regulation. High LYAR expression correlated with poor disease-free and overall survival, underscoring its prognostic value. GSEA revealed LYAR’s involvement in critical cellular processes and pathways, including DNA repair, cell cycle, and mTORC1 signaling. Correlation analysis identified genes positively and negatively associated with LYAR, leading to the discovery of temsirolimus and WYE-354, mTOR inhibitors, as potential therapeutic agents for CRC. Furthermore, LYAR expression predicted increased sensitivity to cetuximab in RAS wild-type metastatic CRC, indicating its utility as a biomarker for treatment responsiveness. Conclusions: LYAR’s upregulation in CRC highlights its potential as a biomarker for prognosis and therapeutic targeting, offering insights into CRC pathology and suggesting new avenues for treatment optimization.


  • Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues

    by Wang-Yang Ye, Hui-Ping Lu, Jian-Di Li, Gang Chen, Rong-Quan He, Hua-Yu Wu, Xian-Guo Zhou, Min-Hua Rong, Li-Hua Yang, Wei-Ying He, et al.

    Background: To date, the clinical management of advanced hepatocellular carcinoma (HCC) patients remains tough and the mechanisms of E2F transcription factor 1 (E2F1) underlying HCC are obscure. Materials and Methods: Our study integrated datasets mined from several public databases to comprehensively understand the deregulated expression status of E2F1. Tissue microarrays and immunohistochemistry staining was used to validate E2F1 expression level. The prognostic value of E2F1 was assessed. In-depth subgroup analyses were implemented to compare the differentially expressed levels of E2F1 in HCC patients with various tumor stages. Functional enrichments were used to address the predominant targets of E2F1 and shedding light on their potential roles in HCC. Results: We confirmed the elevated expression of E2F1 in HCC. Subgroup analyses indicated that elevated E2F1 level was independent of various stages in HCC. E2F1 possessed moderate discriminatory capability in differentiating HCC patients from non-HCC controls. Elevated E2F1 correlated with Asian race, tumor classification, neoplasm histologic grade, eastern cancer oncology group, and plasma AFP levels. Furthermore, high E2F1 correlated with poor survival condition and pooled HR signified E2F1 as a risk factor for HCC. Enrichment analysis of differentially expressed genes, coexpressed genes, and putative targets of E2F1 emphasized the importance of cell cycle pathway, where CCNE1 and CCNA2 served as hub genes. Conclusions: We confirmed the upregulation of E2F1 and explored the prognostic value of E2F1 in HCC patients. Two putative targeted genes (CCNE1 and CCNA2) of E2F1 were identified for their potential roles in regulating cell cycle and promote antiapoptotic activity in HCC patients.


  • Metadherin Promotes the Development of Bladder Cancer by Enhancing Cell Division

    by Shi-Shuo Wang, Gao-Qiang Zhai, Gang Chen, Zhi-Guang Huang, Yu Zhang, Li-Jie Zhang, Yi-Wu Dang, Sheng-Hua Li, Hai-Biao Yan

    Background: Bladder cancer (BLCA) is a malignant tumor occurring in bladder mucosa. Metadherin (MTDH) has been implicated in tumor progression; however, its molecular biological mechanisms in BLCA remain unclear. Materials and Methods: Cell functions were tested after BLCA cells were transfected by both short hairpin RNAs and small interfering RNAs to silence MTDH. Furthermore, in-house RNA sequencing (RNA-seq) was performed with T24 cells after the knockdown of MTDH. In addition, MTDH-related pathways were explored. Finally, MTDH mRNA and protein expression levels were examined using multiple detection methods in BLCA tissues. Results: MTDH knockdown could largely inhibit cell proliferation, viability, and migration and induce apoptosis of BLCA cells. In-house RNA-seq showed that MTDH knockdown led to extracellular matrix organization and cell division. The integrated analysis showed that the comprehensive expression of MTDH at the mRNA level was 0.47 and that at the protein level was 0.54, based on 11 platforms, including 1485 BLCA and 180 non-BLCA samples. Conclusions: MTDH promotes the growth of BLCA cells through the pathway of cell division. This study provides new directions and biomarkers for future treatment.


  • Open Access

    Detection of Complement C1q B Chain Overexpression and Its Latent Molecular Mechanisms in Cervical Cancer Tissues Using Multiple Methods

    by Si-Tong Lin, Zi-Qian Liang, Xiao-Yu Chen, Xin-Qing Ye, Yu-Yan Pang, Jia-Yuan Luo, Jun-Hong Chen, Yi-Wu Dang, Gang Chen

    Aim. The aim of this study is to demonstrate the expression and clinicopathological significance of complement C1q B chain (C1QB) in cervical cancer. Methods. In total, 120 cervical cancer tissues, as well as 20 samples each of high-grade squamous intraepithelial lesions (HSILs), low-grade squamous intraepithelial lesions (LSILs), and benign cervical tissue, were collected to evaluate the expression of C1QB protein via immunohistochemical staining. We conducted an integrated analysis of C1QB mRNA expression in cervical cancer using public microarrays and RNA-seq data sets by calculating standard mean differences (SMDs). Simultaneously, we explored the relations of C1QB with clinicopathological parameters and the expression of P16, Ki-67, and P53. Results. The expression of C1QB protein was higher in cervical cancer samples than that in benign cervical tissue, LSIL, and HSIL samples ( ). A combined SMD of 0.65 (95% CI: [0.52, 0.79], ) revealed upregulation of C1QB mRNA in cervical cancer. C1QB expression may also be related to the depth of infiltration, lymphovascular invasion, and perineural invasion in cervical cancer ( ). We also found that C1QB protein expression was positively correlated with P16 and Ki-67 expression in cervical cancer ( ). The gene set enrichment analysis showed that C1QB may participate in apoptosis and autophagy. A relationship was predicted between C1QB expression and drug sensitivity to cisplatin, paclitaxel, and docetaxel. Conclusion. We confirmed the overexpression of C1QB in cervical cancer at both mRNA and protein levels for the first time. C1QB may serve as an oncogene in the tumorigenesis of cervical cancer, but this possibility requires further study.


  • Open Access

    Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma

    by Si-Wei Huang, Gang Chen, Jian-Di Li, Li-Ting Qin, Zhi-Guang Huang, Su-Ning Huang, Wei Lu, Jiang-Hui Zeng, Bin-Yu Mo, Yi-Wu Dang, et al.

    Background. Currently, the benefits of nasopharyngeal carcinoma (NPC) therapy are limited, and it is necessary to further explore possible therapeutic targets. Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been extensively studied in other cancer species, but little has been explored in NPC. The aim of this study was to verify the expression level of ARNT2 and its underlying mechanism in NPC. Methods. Datasets containing ARNT2 mRNA expression levels were retrieved and collected from various databases to explore the expression status of ARNT2 in NPC. ARNT2-related coexpressed genes, differential expressed genes, and target genes were obtained for functional enrichment analysis. The potential target gene of ARNT2 and their regulatory relationship were studied through ChIP-seq data. CIBERSORTx was used to assess the immune infiltration of NPC, and the association with ARNT2 expression was calculated through correlation analysis. Results. ARNT2 was upregulated and possessed an excellent discriminatory capability in NPC samples. ARNT2 positively correlated target genes were clustered in pathways in cancer, while negatively correlated target genes were enriched in immune-related pathway. The ChIP-seq information of ARNT2 and histone showed that prostaglandin-endoperoxide synthase 2 (PTGS2) was a potential target gene of ARNT2. CIBERSORTx revealed the immunity status in NPC, and ARNT2 expression was correlated with infiltration of five immune cells. Conclusions. ARNT2 is overexpressed in NPC and may regulate PTGS2 to participate in the cancer process. ARNT2 serves as a key oncogenic target in NPC patients.


  • Open Access

    Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways

    by Fei-Yan He, Gang Chen, Rong-Quan He, Zhi-Guang Huang, Jian-Di Li, Wei-Zi Wu, Ji-Tian Chen, Yu-Lu Tang, Dong-Ming Li, Shang-Ling Pan, et al.

    Background: Immediate early response 3 (IER3) is correlated to the prognosis of several cancers, but the precise mechanisms underlying the regulation by IER3 of the occurrence and development of hepatocellular carcinoma (HCC) remain unknown. Methods: The expression level of IER3 was examined by using in-house immunohistochemistry (IHC), public gene chip, and public RNA-sequencing (RNA-seq). The standardized mean difference (SMD) was calculated to compare the expression levels of IER3 between HCC patients and controls. The summary receiver operating characteristics (sROC) was plotted to comprehensively understand the discriminatory capability of IER3 between HCC and non-HCC group. The Kaplan–Meier curves and the combined hazard ratios (HRs) were used to determine the prognostic value of IER3 in HCC. Moreover, differentially expressed genes (DEGs) and co-expression genes (CEGs) were used to explored the molecular mechanisms of IER3 underlying HCC. hTFtarget was used to predict the transcription factors (TFs) of IER3. The binding site of TFs and the IER3 promoter region was forecasted using the JASPAR website. The relevant ChIP-seq data were used to determine whether TF peaks were present in the IER3 transcription initiation. Results: A significantly increased expression of IER3 protein was found in HCC tissue relative to non-HCC tissue as detected by IHC (p < 0.001). Compared to 1,263 cases of non-HCC tissues, IER3 in 1483 cases of HCC tissues was upregulated (SMD = 0.42, 95% confidence interval [CI] [0.09–0.76]). The sROC showed that IER3 had a certain ability at differentiating HCC tissues (area under the curve (AUC) = 0.65, 95% CI [0.61–0.69]). Comprehensive analysis of the effect of IER3 on the prognosis of patients with HCC demonstrated that higher IER3 expression was associated with poor prognosis in HCC (HRs = 1.30, 95% CI [1.03–1.64]). Pathway enrichment analysis revealed that IER3-related genes were mostly enriched in the PI3K-Akt signaling pathway, cancer-related signaling pathways, the p53 signaling pathway, and other signaling pathways. Regulatory factor X5 (RFX5) was identified as a possible regulator of IER3-related TF. Conclusion: IER3 may be a potential prognostic marker for HCC. The molecular mechanisms of IER3 in HCC warrant further study.


  • Multi-parameter diffusion and perfusion magnetic resonance imaging and radiomics nomogram for preoperative evaluation of aquaporin-1 expression in rectal cancer

    by Yidi Chen, Basen Li, Zijian Jiang, Hui Li, Yiwu Dang, Cheng Tang, Yuwei Xia, Huiting Zhang, Bin Song, Liling Long

    Purpose The overexpression of aquaporin-1 (AQP1) is associated with poor prognosis in rectal cancer. This study aimed to explore the value of multi-parameter diffusion and perfusion MRI and radiomics models in predicting AQP1 high expression. Methods This prospective study was performed from July 2019 to February 2021, which included rectal cancer participants after preoperative rectal MRI, with diffusion-weighted imaging, intravoxel incoherent motion (IVIM), diffusion kurtosis imaging (DKI), and dynamic contrast-enhanced (DCE) sequences. Radiomic features were extracted from MR images, and immunohistochemical tests assessed AQP1 expression. Selected quantitative MRI and radiomic features were analyzed. Receiver operating characteristic (ROC) curves evaluated the predictive performance. The nomogram performance was evaluated by its calibration, discrimen, and clinical utility. The intraclass correlation coefficient evaluated the interobserver agreement for the MRI features. Results 110 participants with the age of 60.7 ± 12.5 years been enrolled in this study. The apparent diffusion coefficient (ADC), IVIM_D, DKI_diffusivity, and DCE_Ktrans were significantly higher in participants with high AQP1 expression than in those with low expression (P < 0.05). ADC (b = 1000, 2000, and 3000 s/mm2), IVIM_D, DKI_diffusivity, and DCE_Ktrans were positively correlated (r = 0.205, 0.275, 0.37, 0.235, 0.229, and 0.227, respectively; P < 0.05), whereas DKI_Kurtosis was negatively correlated (r = − 0.22, P = 0.021) with AQP1 expression. ADC (b = 3000 s/mm2), IVIM_D, DKI_ diffusivity, DKI_Kurtosis, and DCE_Ktrans had moderate diagnostic efficiencies for high AQP1 expression (AUC = 0.715, 0.636, 0.627, 0.633, and 0.632, respectively; P < 0.05). The radiomic features had excellent predictive efficiency for high AQP1 expression (AUC = 0.967 and 0.917 for training and validation). The model-based nomogram had C-indexes of 0.932 and 0.851 for the training and validation cohorts, which indicated good fitting to the calibration curves (p > 0.05). Conclusion Diffusion and perfusion MRI can indicate the aquaporin-1 expression in rectal cancer, and radiomic features can enhance the predictive efficiency for high AQP1 expression. A nomogram for high aquaporin-1 expression will improve clinical decision-making. Graphical abstract